News » Largs » Articles »

MSP welcomes cancer drug approval

Published: 24 Aug 2012 15:300 comments

After being attacked by SNP MSP Kenneth Gibson over an inaccurate leaflet about a cancer drug Tory MSP Jackson Carlaw has commented on the prostate treatment becoming available.

Tory MSP Jackson Carlaw

Conservative MSP Jackson Carlaw has pointed out that his door to door leaflet which highlighted a prostate cancer drug was printed before a new decision was taken to allow it.

In a statement after he was criticised by SNP MSP Kenneth Gibson he said:"At the start of last week I am delighted to report that the Scottish Medicines Consortium (SMC) reversed its earlier decision and approved Abiraterone for use by NHS Scotland in the treatment of men suffering from prostate cancer. Although Scotland was the last part of the UK to secure approval this is welcome news.

"In my leaflet where I quoted from a speech given earlier in the year, I also drew attention to my support for a Scottish Cancer Drugs Fund similar to that operating in England which to date the Scottish government has declined to introduce.

"The approval process for new cancer treatments can be prolonged and thousands of individuals suffering from a variety of cancers have benefited from the Cancer Drugs Fund in England. It ensures that sufferers can access the life prolonging drugs they urgently need. I would like to see a similar fund in Scotland.

"For prostate cancer sufferers last week's change of heart by the SMC is welcome news indeed. The campaign for greater support for other cancer sufferers continues."

Jump to first paragraph.

Comments

Have your say - post a comment on this article

Registered users log in here
If you are registered with us, you can login here. If you are not registered, please do so now. Once logged in you wont have to complete word verification each time you post.

Prefer not to register?
Usernames must be 6 - 15 characters. Registration only takes a few minutes. Registered users can also take part in competitions and other features of the site.